Home Cart Sign in  
Chemical Structure| 1532533-72-4 Chemical Structure| 1532533-72-4

Structure of Umbralisib tosylate
CAS No.: 1532533-72-4

Chemical Structure| 1532533-72-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Umbralisib tosylate is a novel phosphatidylinositol 3-kinase delta (PI3Kdelta) inhibitor under development at TG Therapeutics. In 2021, the product received accelerated approval in the U.S. for the oral, once-daily treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen and for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy. Launch took place short after. In 2021, TG Therapeutics completed a rolling submission in the U.S in combination with ublituximab for the treatment of chronic lymphocytic leukemia (CLL). The product is in phase III clinical trials, as monotherapy or in combination with ublituximab, for the treatment of CLL. The product is also in phase II/III clinical trials, as monotherapy or in combination with ublituximab, for the treatment of relapsed or refractory small lymphocytic lymphoma and B-cell lymphomas, including MZL, FL, diffuse large B-cell lymphoma and mantle cell lymphoma. The company refers to the combination regimen of ublituximab and TGR-1202 as TG-1303. The drug is also in phase II clinical development for the treatment Waldenstrom macroglobulinemia. Phase I clinical trials are ongoing for the treatment of Hodgkin's lymphoma. Phase I clinical trials were completed for the treatment of patients with select relapsed or refractory solid tumors, such as adenocarcinoma of the pancreas, adenocarcinoma of the colon, rectum, gastric and GE junction cancer, and GI Stromal Tumor (GIST). In 2016, orphan drug designation was assigned to the compound in the U.S. for the treatment of CLL. In 2017, additional orphan drug designation was granted in the U.S. for the treatment of CLL and DLBCL, in combination with ublituximab. In January 2019, the FDA granted breakthrough therapy designation to the product for the treatment of adult patients with MZL who have received at least one prior anti-CD20 regimen. The compound was granted additional orphan drug designation in the U.S. for the treatment of treatment of nodal, extranodal, and splenic MZL in 2019, and for the treatment of FL in 2020. Originated by Rhizen Pharmaceuticals, the product was jointly developed by Rhizen Pharmaceuticals and TG Therapeutics since 2012. In 2014, exclusive global development and commercialization rights (excluding India) were licensed to TG Therapeutics. In 2020, the product received fast track designation in US by TG Therapeutics for the treatment of adult patients with CLL in combination with ublituximab.

Synonyms: TGR-1202 tosylate; RP5264 tosylate

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Umbralisib tosylate

CAS No. :1532533-72-4
Formula : C38H32F3N5O6S
M.W : 743.75
SMILES Code : S(=O)(=O)(O)C1=CC=C(C)C=C1.NC1=C2C(=NN([C@@H](C)C3=C(C(=O)C=4C(O3)=CC=C(F)C4)C5=CC(F)=CC=C5)C2=NC=N1)C6=CC(F)=C(OC(C)C)C=C6
Synonyms :
TGR-1202 tosylate; RP5264 tosylate

Safety of Umbralisib tosylate

Related Pathways of Umbralisib tosylate

DNA
PI3K-AKT
Hedgehog

Isoform Comparison

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.34mL

0.27mL

0.13mL

6.72mL

1.34mL

0.67mL

13.45mL

2.69mL

1.34mL

 

Historical Records

Categories